2022
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients
2021
GSOR10 Presentation Time: 3:15 PM Single Implant Hybrid Interstitial Brachytherapy for Cervical Cancer during the COVID-19 Pandemic: An Institutional Approach
Damast S, Tien C, Young M, Altwerger G, Ratner E. GSOR10 Presentation Time: 3:15 PM Single Implant Hybrid Interstitial Brachytherapy for Cervical Cancer during the COVID-19 Pandemic: An Institutional Approach. Brachytherapy 2021, 20: s54. PMCID: PMC8215885, DOI: 10.1016/j.brachy.2021.06.086.Peer-Reviewed Original Research